Kindred Biosciences Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Kindred Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KIN, but not buy additional shares or sell existing shares.
View analyst ratings for Kindred Biosciences or view top-rated stocks.

Wall Street analysts have given Kindred Biosciences a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kindred Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Kindred Biosciences saw a decline in short interest in July. As of July 15th, there was short interest totaling 1,030,000 shares, a decline of 15.6% from the June 30th total of 1,220,000 shares. Based on an average daily trading volume, of 1,350,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 2.8% of the company's stock are short sold.
View Kindred Biosciences' Short Interest.

Kindred Biosciences, Inc. (NASDAQ:KIN) released its quarterly earnings data on Monday, May, 10th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.24). The biopharmaceutical company had revenue of $2.40 million for the quarter, compared to analyst estimates of $4.60 million. Kindred Biosciences had a negative trailing twelve-month return on equity of 8.50% and a negative net margin of 19.96%.
View Kindred Biosciences' earnings history.

Kindred Biosciences' stock was trading at $8.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KIN stock has increased by 14.0% and is now trading at $9.22.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued 12 month target prices for Kindred Biosciences' stock. Their forecasts range from $9.25 to $15.25. On average, they expect Kindred Biosciences' share price to reach $10.75 in the next year. This suggests a possible upside of 16.6% from the stock's current price.
View analysts' price targets for Kindred Biosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Kindred Biosciences include PMV Pharmaceuticals (PMVP), Zymeworks (ZYME), Constellation Pharmaceuticals (CNST), Y-mAbs Therapeutics (YMAB), MacroGenics (MGNX), Avid Bioservices (CDMO), Innoviva (INVA), Day One Biopharmaceuticals (DAWN), Harmony Biosciences (HRMY), Prelude Therapeutics (PRLD), Aurinia Pharmaceuticals (AUPH), Amneal Pharmaceuticals (AMRX), Nurix Therapeutics (NRIX), Madrigal Pharmaceuticals (MDGL) and uniQure (QURE).
View all of KIN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), OPKO Health (OPK), TherapeuticsMD (TXMD) and Agile Therapeutics (AGRX).

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Kindred Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include New York State Common Retirement Fund (0.26%), Harvest Management LLC (0.17%), Alliancebernstein L.P. (0.12%), GSA Capital Partners LLP (0.11%), Advisor Group Holdings Inc. (0.10%) and Keebeck Alpha LP (0.05%). Company insiders that own Kindred Biosciences stock include Denise Bevers, Park West Asset Management Llc and Richard Chin.
View institutional ownership trends for Kindred Biosciences.

KIN stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund. Company insiders that have sold Kindred Biosciences company stock in the last year include Denise Bevers, Park West Asset Management Llc, and Richard Chin.
View insider buying and selling activity for Kindred Biosciences or view top insider-selling stocks.

KIN stock was purchased by a variety of institutional investors in the last quarter, including Harvest Management LLC, GSA Capital Partners LLP, Advisor Group Holdings Inc., Keebeck Alpha LP, Mint Tower Capital Management B.V., and Alliancebernstein L.P..
View insider buying and selling activity for Kindred Biosciences or or view top insider-buying stocks.

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KIN stock can currently be purchased for approximately $9.22.

Kindred Biosciences has a market capitalization of $419.14 million and generates $42.16 million in revenue each year. The biopharmaceutical company earns $-21,800,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

Kindred Biosciences employs 63 workers across the globe.

The official website for Kindred Biosciences is kindredbio.com.

Kindred Biosciences is headquartered at 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010.

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]